On the 5th of August 2020, ContextVision held an Extraordinary General Meeting in Stockholm.
- The Board’s proposal for adoption of new articles of association was approved
- The Board’s proposal for decision on the share split of the company’s share was approved
- No other matters were processed at the meeting.
For further information, please contact:
Ann-Charlotte Linderoth (CFO)
tel +46 (0)8 7503550, e-mail
ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world.
Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment.
ContextVision is now entering the fast-growing digital pathology market. We are re-investing significantly in our product portfolio of decision support tools and we are dedicated to becoming a leading resource for pathologists to radically develop cancer diagnosis and improve patient care.
The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker COV.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act